Scientists at the Oxford University said their experimental coronavirus vaccine, being developed with UK’s AstraZeneca, has shown in an early trial that it can prompt a protective immune response in hundreds of people who got the shot. With this announcement, there finally appears to be light at the end of the tunnel.
In research published on Monday in the medical journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged between 15 to 55 who were administered the dose.
“Now what this vaccine does particularly well is trigger both arms of the immune system in addition to neutralizing antibodies which other vaccines do, we also see a very strong T-cell response,” says Professor Adrian Hill, Director of the Jenner Institute, Oxford University.
The phase 1 and phase 2 results of the vaccine, called AZD1222, have been published even as the vaccine requires larger trials to test whether it can offer protection against coronavirus. The third phase is currently underway. Britain has already secured a supply of 100 million doses of the vaccine, which is being developed at an unprecedented speed.
Phase 2 and phase 3 trials for the Oxford project kicked off in May.